Information Links
Mims
Main Navigation
Drugs
Conditions
ArticlesGuidelines - Infections and infestations
Quick-reference summaries of key national treatment guidance for infections and infestations including hepatitis B and C.
NICE technology appraisals
Decisions by the National Institute for Health and Care Excellence on NHS access to treatments for infections and infestations.
-
Tenofovir Alafenamide for Treating Chronic Hepatitis B (terminated appraisal) (TA435)
-
Sofosbuvir-Velpatasvir for Treating Chronic Hepatitis C (TA430)
-
Elbasvir-Grazoprevir for Treating Chronic Hepatitis C (TA413)
-
Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir for Treating Chronic Hepatitis C (TA365)
-
Daclatasvir for Treating Chronic Hepatitis C (TA364)
-
Ledipasvir-Sofosbuvir for Treating Chronic Hepatitis C (TA363)
-
Simeprevir in Combination with Peginterferon Alfa and Ribavirin for Treating Genotypes 1 and 4 Chronic Hepatitis C (TA331)
-
Sofosbuvir for Treating Chronic Hepatitis C (TA330)
-
Peginterferon Alfa and Ribavirin for Treating Chronic Hepatitis C in Children and Young People (TA300)
-
Colistimethate Sodium and Tobramycin Dry Powders for Inhalation for Treating Pseudomonas Lung Infection in Cystic Fibrosis (TA276)
-
Boceprevir for the Treatment of Genotype 1 Chronic Hepatitis C (TA253)
-
Telaprevir for the Treatment of Genotype 1 Chronic Hepatitis C (TA252)
-
Peginterferon Alfa and Ribavirin for the Treatment of Chronic Hepatitis C (TA200 [Part Review of TA75 and TA106]))
-
Tenofovir Disoproxil for the Treatment of Chronic Hepatitis B (TA173)
-
Amantadine, Oseltamivir and Zanamivir for the Treatment of Influenza (TA168 [Review])
MIMS Clinics
Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.
